3 Promising Penny Stocks With Market Caps Larger Than $100M

Over the last 7 days, the market has dropped 1.4%, but it is up 16% over the past year, with earnings forecasted to grow by 18% annually. For investors willing to explore beyond well-known stocks, penny stocks—often smaller or newer companies—can be full of surprises and remain a relevant investment area despite being a somewhat outdated term. In this article, we highlight three penny stocks that stand out for their financial strength and potential for growth.

Here we highlight a subset of our preferred stocks from the screener.

AC Immune (ACIU)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AC Immune SA is a clinical-stage biopharmaceutical company focused on discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases related to protein misfolding, with a market cap of $225.19 million.

Operations: The company generates revenue of CHF 3.70 million from its activities in discovering and developing therapeutic and diagnostic products.

Market Cap: $225.19M

AC Immune, a clinical-stage biopharmaceutical company, is currently unprofitable with limited revenue generation of CHF 4 million. Despite this, the firm has made strides in its pipeline, particularly with ACI-24 for Alzheimer's disease. Recent data from the Phase 1b/2 ABATE trial showed promising safety and immunogenicity results. The company maintains a debt-free balance sheet and has secured significant upfront payments and potential milestones through an agreement with Takeda, offering financial support for ongoing research. However, short-term liabilities exceed assets by CHF 12.1 million, indicating potential liquidity challenges ahead.

• Click here to discover the nuances of AC Immune with our detailed analytical financial health report.
• Learn about AC Immune's future growth trajectory here.

Ceragon Networks (CRNT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Ceragon Networks Ltd. offers wireless transport solutions for cellular operators and other wireless service providers across various regions, with a market cap of approximately $204.51 million.

Operations: The company's revenue is primarily derived from its Wireless Hauling Solutions segment, which generated $335.08 million.

Market Cap: $204.51M

Ceragon Networks Ltd., with a market cap of US$204.51 million, focuses on wireless transport solutions and has secured significant contracts in APAC and Latin America, reflecting strong demand for its services. The company recently announced a five-year agreement valued at US$70 million with a Tier-1 APAC customer to support 4G and 5G network expansion. Despite being unprofitable, Ceragon has reduced losses by 49.4% annually over five years and maintains more cash than total debt, highlighting financial stability. The firm trades below estimated fair value and forecasts suggest substantial earnings growth potential at 107.33% per year.

• Unlock comprehensive insights into our analysis of Ceragon Networks stock in this financial health report.
• Review our growth performance report to gain insights into Ceragon Networks' future.

Pyxis Oncology (PYXS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics for the treatment of solid tumors, with a market cap of $141.28 million.

Operations: Currently, there are no reported revenue segments for this clinical-stage company focused on developing therapeutics for solid tumors.

Market Cap: $141.28M

Pyxis Oncology, Inc., with a market cap of US$141.28 million, operates as a pre-revenue clinical-stage company focused on solid tumor therapeutics. Despite its unprofitability and high share price volatility, analysts anticipate substantial stock price growth potential. The company recently secured US$49.99 million through a private placement involving key investors like BVF Partners L.P., enhancing its financial runway beyond the existing 7 months based on free cash flow estimates. Pyxis's management team is relatively new but has bolstered its strategic capabilities with the appointment of Nelson Azoulay as Chief Business Officer to advance its lead clinical asset.

• Jump into the full analysis health report here for a deeper understanding of Pyxis Oncology.
• Gain insights into Pyxis Oncology's outlook and expected performance with our report on the company's earnings estimates.

Key Takeaways

• Access the full spectrum of 327 US Penny Stocks by clicking on this link.
• Searching for a Fresh Perspective? AI is about to change healthcare. These 130 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com